Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10342 in HR+HER2- advanced breast cancer after endocrine therapy failure
CTR20212153Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10342 in breast cancer, Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Sep 2021; status: terminated.
02
Drugs
HS-10342
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20212153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212153.